{"name":"Cullinan Oncology, Inc.","slug":"cullinan","ticker":"CGEM","exchange":"NASDAQ","domain":"cullinanoncology.com","description":"Cullinan Oncology, Inc. is a precision oncology company focused on developing innovative therapies for patients with cancer. The company's pipeline includes several promising candidates, with a focus on solid tumors. Cullinan Oncology has established itself as a player in the precision oncology space, with a growing portfolio of assets. The company's top drugs include its lead candidate, CGEM-001.","hq":"Cambridge, MA","founded":0,"employees":"","ceo":"Owen Hughes","sector":"Precision Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.2B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":187402000,"netIncome":-219879000,"cash":88332000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"CGEM-001 patent cliff ($0.00 at risk)","drug":"CGEM-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Cullinan Oncology Announces FDA Clearance of IND for CGEM-001","summary":"Cullinan Oncology announced that the FDA has cleared the Investigational New Drug (IND) application for CGEM-001, enabling the company to initiate a Phase 1 clinical trial.","drugName":"CGEM-001","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Cullinan Oncology Reports Third Quarter 2023 Financial Results","summary":"Cullinan Oncology reported its third-quarter 2023 financial results, with a focus on its pipeline progress and operational updates.","drugName":"","sentiment":"neutral"}],"realNews":[{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-20","type":"pipeline","source":"PR Newswire","summary":"Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanc","headline":"Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQZGdtS2g1cmF5aWJwb1J1emNMVmdaRmlRNFBnNEpBRjVNLW96NjNhSUJGN3FOZHFfRGpwd2pCRTQyRW45ZV90aTZkVFQtSnprekJrM2NlWjZmNFpYNGVsOHRjdDNTWm05NTJySnBRNlQ0bnE1OWNudUZkM3dzVHpKYU8wSmRONDRqc3VuejI1TFJXUk04aUs0Ym9yQWIyNUZVVW1vLVRTWnJiVkNVNEVYVXFocWRrNWtlWHM2QlhlYnVlZHRpRkV5TkNwY3hZeEdieldkVHVPc3MwM1ZxV0RQaV8wNXpZajRDYW5JZXNOU3ZQMU5POHNYZzdkNWNEU0RRWXp5LUFJdmxMX0MxXzRBekMwdjN4bkZKZUhreWtlUk93YmVYSTdwaGcwazB0NnhXc1djYzcwOE1GUEdJNWZxVFV5OEk?oc=5","date":"2025-10-12","type":"trial","source":"PR Newswire","summary":"Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025 - PR Newswire","headline":"Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Act","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxPRjBNSGlSTG1MN1FSRlNpS2I2OEM2MElJRDlLZEc5MFZvcUxUZXJvd2ZRRWhkdktFci1XTmw4UU4tVENzc3pkUVpuQTRzQ3FTaEN0RkNmbnNCMzg0UWlQRWpQY1k2RnUyLWNwb1VvLVNmRk5scC0zTElEUGVFR0dyT0t6NWkzMW5vNzF1MVJfQWZNRjExdWhSUmtVUVlxUnNwNV9HdHVuX3RPTUNBVE9tQmdzeEotX256M24xOWx1WHJBMWFqbTBCU09kTENQREtaMzRINmNCWlRJMExlNV9rNE1HOGpoR1pERnA3SnllNXRLeHNSZmpackZPSFlaMnVkeUFFY1Zn?oc=5","date":"2025-09-09","type":"trial","source":"PR Newswire","summary":"Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer - PR Newswire","headline":"Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNaEhEb1Q0X1p1c2pXUXpoVXBWRW40YnRKOTRZbGlneVZyN1ZwUW5sZWNBaUh3TEtsUUZOdkpYV2hGTnpvYW1YWkJkUy1YNm1yRGdPLTNnRHFPTy1HTF9Od01ybGlxMGp1RG5WMUdXeUc1aGl5T3REcjJncW1RZERGWmJVbHZxemNNdzE5Zms4QnRVRk44ckJJT3loUXJ6VV9la3Ftc1lPYW1rUHF6aXVZbWRuZnU1NXZYNW12ZlZqalpLbjdnT1hyTDFERXdXN1g1RFM5bmQ1NGNIZkdFa1RkT0lVTFFLeHQ2QzVqbWRhM3NWUUhEVVZZYWEzT1NRVUVSTm1vbmhwTXktTTNoMTlnb1c5S0dSNHc5LVV1T3h6VURVZw?oc=5","date":"2025-07-22","type":"pipeline","source":"PR Newswire","summary":"Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer - PR Newswire","headline":"Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Confe","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxQbVh5QThIRkUyTXdkaXRiTkFucldXdkp2S3JsMDh5a3hJaWJDRFlIZG1hMm9yOUhIRllGRmNMbnQ2S1BGMGJYblo4M3pwMUNmRHdYR3BhRzdWbzBYNFB6X1h3cHJuLURDZS1UZFhqUk5mYXk0SW9MMHBqQklwbER0ZjhkMzFsY2pjUUc5bHpiMUhYTlB1OWpSdnhBbmc1UFZwSmlSLTVIYVZJUlAxRXVsWVBIaGM4VzZHQlp2dFhwWm9MeFdPNVNTWU13VUtKSUVMckh2VTN3OE50dmdnM3F6S1NJWF95ejhnTE1tUHh1ZVhQbk1GekJFcXlrVEVtSng5QjFtTWoySTNNODlYaUFGMGd3?oc=5","date":"2025-06-01","type":"trial","source":"PR Newswire","summary":"Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - PR Newswire","headline":"Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-28","type":"trial","source":"PR Newswire","summary":"Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser","headline":"Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipal","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBoQlJySDliS1RsUFBwVzBQVW5yUVFOT1lISGQ3M3lWbkNlM2FVRUtDVklIX0lUUWlZR3NVSFN0Q0oxODJ5aEJuZFpmMF93UXRxcEN5aEtYMWxDeGJm?oc=5","date":"2024-06-04","type":"pipeline","source":"TradingView","summary":"CGEM Stock Price and Chart — NASDAQ:CGEM - TradingView","headline":"CGEM Stock Price and Chart — NASDAQ:CGEM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPa0wya25kOVQ4eEtWQlR2MGRRSi04ck1RdnhvQ3ZveUQ5aUNBd1RYMkJkZWhhMGRZSGE0c01NOTZxTE90SzRDT1M1S2t0cVRUMzJCRlFDT3lUazg3TUUtbU96OWFtX3l0czR6Z3BqSVdQdVdSbjNZOFZFWlJhZlpZU2JUazRFN2I3UlZOR0dZYXBCbG5VTy1z?oc=5","date":"2024-04-16","type":"pipeline","source":"BioPharma Dive","summary":"Cullinan changes name, pivots to autoimmune disease - BioPharma Dive","headline":"Cullinan changes name, pivots to autoimmune disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOR2hRbjU0TWthRXBtQWNBR0I4cEJiTzZXOUpQREJpWWNvRDRKQl9RWGQyeFdHMmNNYkM5SXpKUlFHVkxWalo3NnRNN1MzcGNMY25HTDBEdjRHM2lLMFNXdFlQcXBGVDZDZ3pUS3hWZklRYlptY09BTy1fRllzbktnZy1tM2FNY2h2b2FMV3dHVXYtTzJ5bmJmVzNNbW1HcnJRS2FsR1V5QVgzd3laV1FkNF9vYk51YVQ0T05WUFlKSzhMa0FmRzhwbVlVc3lSSVJFTEJMb3hSZEVhN2JsWlY4LWVxU0R1WXhyRlo3VF9DODluM2pFYVl6ckRTd1lPdXpfOUszM0hhd3NDSTRubFZyZVkzUTlkcktZY2dhMUR6eV9mVHJoZXlIT1dB?oc=5","date":"2023-08-03","type":"trial","source":"PR Newswire","summary":"REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations - PR Newswire","headline":"REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR E","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNQ2tlRkM3aHhPczFjTlNfS284MVBaYk1oWWl5Zmk3TElTMjRYUnVHemZ1ZkFOb0lQS29JUnNfcmZWbEh2QlZrQUhjSUJ0S2UxcmUyNVhaV1lENDBPRTFhSTQ5OGIta0xjZjBZdDRPVHNuM1R5X1ZVckpOb1FzdFpUSWNEcG9nUQ?oc=5","date":"2023-01-23","type":"deal","source":"Yahoo Finance","summary":"12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds - Yahoo Finance","headline":"12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxNS3lGdUN6Sk13NWtrVFF4MG9taUJhMVBCdnhxTV9wd3pEb2Jvckdma1pxNnc1U2F3UmFtdVVtZkhPVzAybnp0UmFyRmNBX3NiV3g3Q24tTFVwaV9XdTNOUUxwU1pVS2JvOWJ0SmhZZHJiU21EUUltZGVHM3ZBQVlEZ3psLUVVWldVMXlRc0J6MjJFQnBGbTZybFlRbEFiOWJZZVlibkNKSHdRV1k1allmWVlKV3ZTbWZsTDFZcGhmaFZlV1RVeFZVUDdqQk55Y0xOb1c1WHZ6anUwcGJrMWtXbFFtTzl4M0FKTGJ1ZGxmOEwzOE1PZkRkamhlZVhGYlRqck1IY1g4T3QxX0FZNFItLWduOTB5NHNITnJsQWktNUlORHVaeU50R0xlcldDamZweVhzb2dLV3UtRGxQQ3ZsSjVWNEVkV0tzVUJ1Y0U4MjRIWFhMcEZUclU5WW04OUk?oc=5","date":"2022-05-12","type":"pipeline","source":"GlobeNewswire","summary":"Cullinan Oncology and Taiho Pharmaceutical Announce - GlobeNewswire","headline":"Cullinan Oncology and Taiho Pharmaceutical Announce","sentiment":"neutral"}],"patents":[{"drugName":"CGEM-001","drugSlug":"cgem-001","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Clovis Oncology","Foundation Medicine","Guardant Health"],"therapeuticFocus":["Solid Tumors"],"financials":{"source":"sec_edgar","revenue":0,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":0,"period":"2022-12-31"},{"value":18943000,"period":"2021-12-31"},{"value":0,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":187402000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-219879000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":88332000,"cashHistory":[],"totalAssets":448374000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}